Connect with us


Citeline and Norstella merge in $5billion deal




Norstella, a developer of end-to-end solutions that improve access to life-saving therapies for patients, has announced the completion of its merger with clinical trial intelligence company, Citeline.

The merger will allow Norstella to prioritise rapid innovation to help guide life sciences companies through the entire drug development process so patients can get access to therapies quicker.

The deal makes the $5 billion global company one of the world’s largest pharma intelligence solutions providers on the market.

Norstella CEO, Mike Gallup, said:

“We believe that patient access starts with identifying unmet needs and doesn’t end until a patient has a therapy in hand.

“As the industry moves toward highly targeted therapies focused on smaller patient populations, our clients need solutions that provide actionable answers to critical business questions to help bring drugs to market quicker—ultimately helping patients receive treatment sooner.”

As a combined organisation, Norstella’s solutions will enable pharma stakeholders to identify unmet clinical needs early, construct clinical trials with informed endpoints that support downstream reimbursement decisions and precisely identify eligible patients for clinical trials.

Jay Nadler, Executive Chair of Norstella and Ramsey Hashem, CEO of Citeline, said:

“This union is an opportunity for both Citeline and Norstella to advance their shared mission of making therapies available to the patients who need them.

“We feel an urgency to make an impact, and we believe that we can bring innovation that will change patients’ lives.”

Gallup added:

“A key philosophy at Norstella is to innovate in partnership with our clients; we will continue to ask our clients where there is a gap and how we can close it.

“Together, we’re aiming to create a healthcare marketplace that’s more innovative and accessible for all.”

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending stories